Drug Safety Assessment of Medication-Associated Body-Composition Changes During Long-Term Therapy

Abstract

Medication-associated changes in body composition are increasingly recognized as clinically significant adverse effects during long-term therapy. This review systematically evaluates the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, treatment strategies, recent advances, and guideline recommendations relevant to the drug safety assessment of body-composition alterations. The aim is to provide evidence-based, mechanism-focused, and practice-oriented insights for clinicians to optimize patient outcomes, minimize risks, and enhance the safety profile of chronic pharmacotherapy.

Introduction

Long-term pharmacotherapy forms the cornerstone of management for a wide array of chronic diseases. However, several classes of medications including glucocorticoids, antipsychotics, antidiabetics, and antiretrovirals have been associated with significant alterations in body composition, such as increased adiposity, sarcopenia, or redistribution of fat. These changes can adversely affect cardiometabolic risk, quality of life, and therapeutic adherence. Understanding the clinical significance, mechanisms, and management of these effects is essential for healthcare professionals engaged in chronic disease management.

Epidemiology / Disease Burden

Medication-induced body composition changes are prevalent across multiple therapeutic areas. For example, up to 50% of patients on long-term glucocorticoids may develop central obesity or myopathy. Second-generation antipsychotics such as olanzapine are associated with significant weight gain in 40–80% of patients, often within the first year of therapy. Antiretroviral therapy (ART) in HIV-infected individuals has shifted the disease burden from wasting to lipodystrophy, with an estimated prevalence of 20–40% depending on the regimen. These alterations contribute to increased cardiovascular morbidity, insulin resistance, and impaired physical function, imposing a notable burden on healthcare systems.

Pathophysiology

The biological mechanisms underlying medication-induced body composition changes are multifactorial. Glucocorticoids promote adipogenesis, inhibit protein synthesis, and enhance proteolysis, leading to central obesity and muscle atrophy. Antipsychotics modulate hypothalamic pathways that regulate appetite, satiety, and energy expenditure, often via antagonism of histaminergic and serotonergic receptors. Insulin analogues and sulfonylureas can promote adipose tissue deposition by stimulating lipogenesis and reducing lipolysis. Protease inhibitors and nucleoside reverse transcriptase inhibitors in ART regimens disrupt adipocyte differentiation and mitochondrial function, resulting in lipoatrophy or lipohypertrophy. Genetic susceptibility, baseline metabolic status, and drug-specific pharmacodynamics further modulate these effects.

Risk Factors

Risk factors for medication-associated body composition changes include drug class, dosage, duration of therapy, age, baseline body mass index (BMI), pre-existing metabolic disorders, and genetic predispositions. Pediatric and elderly populations are particularly susceptible due to differences in body composition and metabolic reserve. Concomitant use of multiple obesogenic or catabolic agents amplifies risk. For example, co-administration of corticosteroids and antipsychotics potentiates central adiposity and insulin resistance. Variability in CYP450 enzyme activity and pharmacogenomic profiles may influence individual response and risk stratification.

Clinical Features

Patients may present with overt weight gain, visceral fat accumulation, truncal obesity, peripheral lipoatrophy, or sarcopenia. In antipsychotic-treated populations, rapid weight gain often precedes metabolic syndrome. Glucocorticoid-induced myopathy typically manifests as proximal muscle weakness. ART-related lipodystrophy may include facial lipoatrophy, dorsocervical fat pad enlargement (buffalo hump), and abdominal adiposity. These changes can be distressing, leading to reduced treatment adherence, social stigma, and psychological distress. Importantly, they increase the risk of cardiovascular events, type 2 diabetes, and osteoporosis.

Diagnosis

Early recognition requires a high index of suspicion and systematic monitoring. Clinical assessment includes serial measurements of weight, waist circumference, and BMI. Advanced modalities such as dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), and MRI permit detailed quantification of fat and lean mass distribution. Laboratory evaluations should assess glucose tolerance, lipid profiles, and markers of muscle injury. Implementation of structured screening protocols at therapy initiation and regular intervals enhances detection and facilitates timely intervention.

Treatment & Management

Management strategies are multifaceted and must be individualized. Non-pharmacological interventions, including dietary counseling, structured exercise programs, and behavioral therapy, remain foundational. Pharmacological options may include switching to alternative agents with lower risk profiles or dose reduction where feasible. In certain cases, adjunctive use of agents such as metformin has demonstrated efficacy in mitigating weight gain associated with antipsychotics. For glucocorticoid-induced myopathy, resistance training and vitamin D optimization are beneficial. Multidisciplinary collaboration is critical to optimize metabolic health and maintain therapeutic efficacy.

Recent Advances / Emerging Therapies

Recent research has focused on developing medications with reduced propensity for adverse body composition effects. Third-generation antipsychotics, such as aripiprazole and lurasidone, exhibit more favorable metabolic profiles. In HIV management, integrase strand transfer inhibitors (INSTIs) are associated with lower rates of lipodystrophy compared to older regimens. Ongoing trials are evaluating the role of GLP-1 receptor agonists and SGLT2 inhibitors in attenuating medication-induced weight gain and improving body composition. Pharmacogenomic-guided prescribing holds promise for personalized risk mitigation.

Guideline Recommendations

Major clinical guidelines underscore the importance of baseline and ongoing assessment of body composition in patients prescribed high-risk medications. The American Diabetes Association and American Psychiatric Association recommend regular metabolic monitoring for patients on antipsychotics. HIV treatment guidelines advocate for routine screening and prompt management of ART-associated lipodystrophy. Shared decision-making, patient education, and close monitoring are integral to safe long-term pharmacotherapy. Documentation of risk assessment and adverse effects should be incorporated into electronic health records for quality assurance and pharmacovigilance.

Conclusion

Medication-associated body composition changes represent a significant challenge in the long-term management of chronic diseases. A nuanced understanding of the epidemiology, mechanisms, risk factors, and clinical implications is essential for optimizing drug safety. Early identification, proactive management, and adherence to guideline-based recommendations can mitigate adverse outcomes and enhance patient quality of life. Ongoing research and emerging therapies offer hope for minimizing these effects and tailoring treatment to individual patient risk profiles.